ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ALXO
ALX Oncology Holdings Inc. (ALXO) Altman Z-score
ALX Oncology Holdings Inc.'s Altman Z-score for fiscal 2020 is 154.45, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2020 | 154.45 | — |
How fiscal 2020’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.99 | — | 1.18 | |
| Retained earnings / total assets | (0.27) | — | −0.38 | |
| EBIT / total assets | (0.10) | — | −0.33 | |
| Market value of equity / total liabilities | 256.63 | — | 153.98 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 154.45 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 77.60 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ALXO ALX Oncology Holdings Inc. | 154× |
| MOLN Molecular Partners AG Sponsored ADR compare | 2.7× |
| KRRO Korro Bio, Inc. compare | −6.7× |
| CUE Cue Biopharma, Inc. compare | −11.9× |
| MSLE Satellos Bioscience Inc. compare | — |
| AVXL Anavex Life Sciences Corp. compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
| ABOS Acumen Pharmaceuticals, Inc. compare | — |
| TLSA Tiziana Life Sciences Ltd compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets